期刊文献+

Fas,FasL在喉癌中的表达及其临床意义 被引量:3

The expression of Fas,FasL in laryngeal carcinoma and its clinical significance
下载PDF
导出
摘要 目的 :研究Fas ,FasL在正常喉黏膜及喉癌组织中的表达及意义。方法 :采用SABC免疫组化法检测 5例正常喉黏膜及 4 0例喉癌组织的Fas ,FasL表达。结果 :Fas在 5例正常喉黏膜中全部表达 ,在 4 0例喉癌中阳性表达 16例 ,阳性率为 4 0 % ,高分化组、临床Ⅰ、Ⅱ期组和未复发组Fas表达阳性率显著大于低分化组 ,临床Ⅲ、Ⅳ期组和复发组 (P<0 .0 5 ) ;FasL在 5例喉正常黏膜中均未见表达 ,在 4 0例喉癌组织中均见不同程度的表达 ,喉癌组织FasL表达强度与喉癌组织学分级、临床分期呈正相关 (r′s =0 .8392 ,0 .86 85 )。结论 :在喉癌的发生与演进过程中存在Fas丢失和FasL表达上调 ,检测Fas ,FasL表达对评价喉癌的恶性程度 。 Objective: To study the expression of Fas,FasL in laryngeal carcinoma and the role of them in the pathogenesis of laryngeal carcinoma . Method: With immunohistochemical staining techniques, 5 cases of normal laryngeal mucosa and 40 cases of laryngeal carcinoma specimen were detected for the expression of Fas and FasL. Results: 5 cases of normal laryngeal mucosa were all Fas-positive. The Fas-positive rate in the laryngeal carcinoma cases was 40%(16/40). The Fas-positive rate of the high differentiation,clinical Ⅰ,Ⅱ stage and unrecurrence group was higher than that of the low differentiation,clinical Ⅲ,Ⅳ stage and recurrence group(P<0.05), and was not relative to the site of the tumors(P>0.1).The normal laryngeal mucosa was FasL-negative, but the laryngeal carcinoma specimen was FasL-positive. There was positive correlation between the degree of the FasL expression and the histological grade,clinical stage (r′s=0.8392;r′s=0.8665).Conclusion: The expression of Fas, FasL correlate with the clinicopathological parameters of laryngeal carcinoma significantly, which suggests that there is the loss of Fas and upregulation of FasL in the genesis and progression of laryngeal carcinoma. The detection of them is of important significance for evaluating the malignancy,prognosis of laryngeal carcinoma and directing the treatment.
出处 《山东大学基础医学院学报》 2003年第3期160-162,共3页 Journal of Preclinical Medicine College of Shandong Medical University
关键词 FAS FASL 喉癌 临床意义 癌组织 SABC免疫组化法 细胞凋亡 Laryngeal neoplasms Neoplasms, squamous cell Immunohistochemistry Antigeas,CD95
  • 相关文献

参考文献10

  • 1肖冰,时永全,赵燕秋,尤涵,刘宪玲,樊代明.Fas基因转导胃癌细胞的表达[J].华人消化杂志,1998,6(5):400-403. 被引量:7
  • 2孙长凯,鞠躬.FasL-Fas/APO-1(CD95)系统[J].生理科学进展,1997,28(2):136-138. 被引量:17
  • 3Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expressit on of the Fas ligand, a novel member of the tumor necrosis factor family [J]. Ce11,1993,75:1169- 1178.
  • 4Bennett MW, O'connell J, O'sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor- infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma[ J]. J Immunol, 1998, 160( 11 ):5669- 5675.
  • 5Trauth BC, Klas C, Peters AM J, et al. Monoclonal antibody mediated tumor regression by induction of apoptosis[ J ]. Science, 1989,245:301 - 305.
  • 6Yonehava S, Ishii A, Yonehara M .A cell killing monoclonal antibody (anti - Fas) to a cell surface antigen co - down regulated with the receptor of tumor necrosis factor [ J]. J Exp Med, 1989,169:1747- 1756.
  • 7Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of Apo - 1, a new member of the nerve growth factor / tumor necros is factor receptor superfamily, in normal and neoplastic cells [J]. Lab Invest, 1993,6 9(4):415 -429.
  • 8Rensing- Ehl A, Frei K, Flury R, et al. Local Fas/Apo- 1 (CD95) ligand - mediated tumor cell killing in vivo [J]. Eur J Immunol, 1995,25:2253 - 2258.
  • 9O'connell J, Benett JM, O'sullivan C, et al. The Fas counterattack: a molecular mechanism of tumor immune privilege [J]. Mol Med, 1997,3:294.
  • 10宋建勋.Fas抗原表位与死亡信号传导的关系[J].免疫学杂志,1997,13(3):206-207. 被引量:6

二级参考文献2

  • 1Ju S T,Nature,1995年,373卷,444页
  • 2Chang J H,J Immunol,1995年,154卷,1239页

共引文献27

同被引文献24

  • 1郑佳,刘复强.Fas/FasL及其临床意义[J].首都医科大学学报,2004,25(3):411-414. 被引量:11
  • 2钱敏飞,王家东,郑璐滢.p27、p53和Bcl-2蛋白在喉癌和切缘组织中的表达[J].中国耳鼻咽喉头颈外科,2005,12(11):721-724. 被引量:5
  • 3Nagate S. Apoptosis by death factor. Cell, 1997, 88: 355-365.
  • 4Lavrik IN, Golks A, Krammer PH. Caspases:pharmacological manipulation of cell death. J Clin Invest, 2005, 115: 2665-2672.
  • 5Sudarshan S, Holman DH, Hyer ML, et al. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. CancerGeneTher, 2005, 12: 12-18.
  • 6Kim R, Emi M, Tanabe K, et al. The role of Fas Ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer, 2004, 100: 2281-2291.
  • 7StrasserA, Jost P J, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity, 2009, 30: 180-192.
  • 8Yoo N J, Lee SH, Jeong EG, et al. Expression of nuclear and cytoplasmic phosphorylated FADD in gastric cancers. Pathol Res Pract, 2007, 203: 73-78.
  • 9Gibcus JH, Menkema L, Mastik MF, et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res, 2007, 13: 6257-6266.
  • 10Gibcus JH, Mastik MF, Menkema L, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer, 2008, 98: 950-955.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部